Moderators: Paul DiSilvestro, MD

Presentations:

• SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (Ramez Eksander, MD)
• Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (Mansoor Mirza, MD)
• Distillation (Rebecca Arend, MD)